This comes amidst the bourse reform plan allowing the listing of pre-profit biotech companies.
Bloomberg reports that Fosun-backed Shanghai Henlius Biotech Inc., is reportedly planning an initial public offering that could make it one of the first companies to benefit from the proposed bourse reform plans allowing the listing of pre-profit biotech companies.
Insider sources revealed to Bloomberg that going public could raise at least $500m that will help Henlius Biotech in its R&D efforts to develop treatments for oncology and autoimmune diseases.
In December, the company raised as much as $140m from Jacobson Pharma Corp in a deal that values the company at more than $1.5b.
Here’s more from Bloomberg:
Do you know more about this story? Contact us anonymously through this link.